Platform & Pipeline
- Home
- Platform & Pipeline
Platform
Screening Strategies
In developing new small-molecule MYC inhibitors, our team has optimized a workflow that can be applied to discovering inhibitors for other high-value disordered protein targets. By coupling computational screening with novel in vivo testing strategies, we can quickly identify potent compounds with favorable drug-like properties and optimize more
relevant parameters simultaneously.
Diverse, Dedicated Compound Library
Our library of 14-3-3 privileged scaffolds allows us to probe how small-molecule drugs of different chemotypes, including natural products, drug-like compounds and molecular fragments, stabilize a wide range of 14-3-3:client complexes. These different approaches can be used to stabilize the full spectrum of 14-3-3 client interactome and inform efficient, and ultimately predictive, structure-chemotype pairing.
Drug Discovery Toolbox
Our drug discovery toolbox combines screening via high-throughput X-ray crystallography as well as biochemical, biophysical, cellular mechanistic, pharmacodynamic and functional assays to power structure-enabled medicinal chemistry optimization efforts.
Pipeline
Our pipeline currently focuses on oncology, where multiple opportunities exist to engage currently undrugged targets that are involved in oncogenic signaling, gene expression, cell cycle dysregulation, and other cancer-driving processes.
More information coming soon.
Exchange factor
Activator of prevalent oncogene
Hit-to-lead
Early clinical
Oncology
BIC
Phosphatase
Cell cycle regulator
Hit exploration
Undrugged
Oncology
FIC
Kinase
Relay for oncogenic signaling
Hit exploration
Preclinical
Oncology
FIC
Kinase
Regulator of endolysosomal processes and vesicular trafficking
Hit exploration
Clinical
Neurodegeneration
BIC
TF
Regulator of cell cycle, proliferation, survival
Target validation
Clinical
Oncology
BIC
TF
Effector of multiple oncogenic signaling pathways
Target validation
Early clinical
Oncology
BIC